Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

68 results about "Eye infection" patented technology

Invasion and growth of microorganisms in the eye; may be clinically inapparent or result in local cellular injury; occurs either on the external surface of the eye or intraocularly with probable inflammation, visual impairment, or blindness.

Ophthalmic, otic or nasal pharmaceutical composition and the use thereof

InactiveUS20100222308A1Effective treatmentPreventing increase of bacterial infection riskAntibacterial agentsBiocideInfective rhinitisNose
The invention provides an ophthalmic, otic or nasal pharmaceutical composition, comprising levofloxacin or the pharmaceutical acceptable salts thereof and loteprednol etabonate, wherein the weight ratio of loteprednol etabonate to levofloxacin is 1:0.2-5. The use of ophthalmic, otic or nasal pharmaceutical composition of the invention in preparation of the medication for treatment of conjunctivitis, keratitis, blepharitis, dacrycystitis, hordeolum, corneal ulcer and ocular infection accompanied with ophthalmitis and even inflammation of the surrounding tissues, to prevent increase of bacterial infection risks and the tissue inflammation of the infected area after the ophthalmic surgeries or ocular injuries, to treat or alleviate the bacterial infection in combination with the tissue inflammation of the infected area, or to treat tympanitis, otitis externa and infective rhinitis.
Owner:SHENZHEN REGOO LAB

Method of treating eye infections with azithromycin

The invention features methods and compositions for treating ocular infections. The method comprises topically administering to an eye of an animal in need of such treatment an ocular infection-treating amount of azithromycin.
Owner:PFIZER INC

Ophthalmic composition containing quinolones and method of use

A preservative-free opthalmic composition for treating eye infections is disclosed. The composition contains a quinolone compound in an amount effective as an antibiotic when the composition is placed in the eye. The composition is rendered isoosmotic with polyhydric alcohol. The composition may be utilized to treat ophthalmic conditions by topically applying the composition to the affected tissues.
Owner:SANTEN PHARMA CO LTD

Gatiflxacin eye gels based on HPMC medium and its preparing method

An ocular Jiatishaxing gel for treating eyelid inflammation, stye, conjunctivitis, dacryocystitis, keratitis, corneal ulcer and trachoma is prepared from Jiatishaxing, HPMC as matrix, antiseptic, isotonic regulator, osmotic promoter, pH regulator and water through dissolving Jiatishaxing in water, adding others, stirring, regulating pH=5-9, filter and adding water.
Owner:SHENYANG PHARMA UNIVERSITY

Parenteral Combination Therapy For Infective Conditions With Drug Resistant Bacterium

The invention describes a pharmaceutical composition to combat multiple-drug-resistant bacteria in non-ocular infective conditions. Compositions comprising glycopeptides, in particular vancomycin, and cephalosporins, in particular ceftriaxone, are disclosed. Such compositions are found to be useful for parenteral administration for hospitalized patients with serious infections. Specifically, this invention also discloses a pharmaceutical composition further including an excipient such as CVMC agent and is available in dry powder form for reconstitution before injection with a suitable solvent. The pharmaceutical compositions of this invention have been found normally to enhance resistance to precipitation in solutions to be administered parenterally. The invention also gives details of the dosage forms stored in sealed containers to be reconstituted before use. The invention further provides a process to manufacture these compositions and also a method of treating a subject having non-ocular infective conditions due to multi drug resistant bacterium.
Owner:VENUS REMEDIES LTD

Oxazolidinones to treat eye infections

The present invention involves a method of treating an ophthalmic infection in a useful warm blooded mammal who is in need of such treatment which comprises topical administration of an ophthalmologically effective amount of an OXAZOLIDINONE.
Owner:PHARMACIA & UPJOHN CO

Ophthalmic or otic and nasal composition containing difluprednate and lavo-ofloxacin and application thereof

The invention provides an ophthalmic or otic and nasal pharmaceutical composition, which comprises lavo-ofloxacin and salts thereof and difluprednate, wherein the weight ratio of the difluprednate to the lavo-ofloxacin is 1:1-1:10. The ophthalmic or otic and nasal medicament composition is applied to treating conjunctivitis, keratitis, eyelid inflammation, dacryocystitis, hordeolum, corneal ulcer and eye infections with inflammations of eyes or surrounding tissues, or preventing increased risk of bacterial infections and tissue inflammations of infected parts after ophthalmic surgeries or eye injuries, or treating or relieving the bacterial infections combined with tissue inflammations of the infected parts after the ophthalmic surgeries, or treating otitis media, otitis externa and infectious rhinitis.
Owner:SHANDONG INST OF PHARMA IND

Antimicrobial composition and methods of use

An antimicrobial composition and methods of use are provided. The antimicrobial composition includes a water-soluble antimicrobial organosilane ammonium compound and a sugar. The composition may be in liquid, foam, ointment or gel form. The composition may include anti-inflammatory medications, alcohol and / or steroids. The antimicrobial composition may be used to treat eye infections in humans and animals. The antimicrobial composition may be applied directly to the surface of the eye. The antimicrobial composition may further be used to treat ocular related articles, including contact lenses, contact cases, instruments, pads and the like. The antimicrobial composition may be applied directly to the surface of the ocular related article during and / or after manufacture.
Owner:REDUXX LLC

Lomefloxacin hydrochloride eye drops and preparation method and application thereof

The invention discloses lomefloxacin hydrochloride eye drops and a preparation method and application thereof. The lomefloxacin accounts for 0.3% of the active components. The preparation also comprises a tackifier, a buffer salt system, a wetting agent, an isoosmotic adjusting agent, a pH adjusting agent and a bacteriostatic agent, and is suitable for treating the external eye infections such asacute and chronic bacterial conjunctivitis, blepharitis, hordeolum, meibomiantis, dacryocystitis, keratitis, keratohelcosis and the like caused by sensitive pathogenic bacteria. The product is characterized in that: by adding the sodium hyaluronate with a tackifying effect and a moisturizing effect, the viscosity of the lomefloxacin hydrochloride eye drops is improved, the fluidics property thereof is changed, the residence time of the eye drops in the eyes is prolonged, the sufficient absorption of the medicine is ensured, the bioavailability is increased, the administration times are reduced, the compliance of a patient is improved, and an effective treatment effect is realized.
Owner:KANGYA OF NINGXIA PHARMA

Macrolide antibiotics sodium hyaluronate eye transfer system

This invention relates to an eye use transmission system of macrolide type antibiotic hyaluronic acid natrium. The goal of this invention is to provide a macrolide type antibiotic eye use medicine preparation with carrier is hyaluronic acid or its salt. It is used to cure germ eye region infection. The macrolide type antibiotic in this invention includes antibiotic that has 14 yuan,15yuan, 16yuan large ring construction features , for example, natural antibiotic bring by streptomycete erythromycin, josamycin, spiramycin, medemycin etc. and semisynthesis derivant from by structure modification of natural antibiotic, such as roxithromycin, azithromycin, clarithromycin, rokitamycin, telithromycin.
Owner:无锡康福特药物科技有限公司

Gel for lysozyme eye and preparation method thereof

The invention relates to a gel for lysozyme eye and a preparation method thereof. The gel for the lysozyme eye is applicable of treating various normal eye infection diseases, such as a pinkeye, an ophthalmia, a ceratitis, a keratohelcosis, a conjunctivitis and the like, which is caused by bacteria, Chlamydia, virus and drug-resistance bacteria. The gel for the lysozyme eye disclosed by the invention uses a solution containing 0.1-10.0% of lysozyme, 0.01-20% of water soluble macromolecule matrix, 0.1-10% of a pH modifier, 0.01-10% of a bacteriostat and 0.1-10% of a viscosity modifier and takes a solution with a pH value of 5.0-6.5 as a buffer solution. With the adoption of the receipt of the gel for the lysozyme eye provided by the invention, the time that drug lysozyme remains on an eye can be prolonged, and the bacteriostat efficiency of the lysozyme on the eye can be improved.
Owner:SHENYANG PHARMA UNIVERSITY

Eye drape for surgical procedures

Eye drapes that cover the conjunctiva and reduce the incidence of eye infection are provided. The eye drape has a flexible material and attached thereto a surgical drape. The flexible material is preferably circular with an opening to expose the cornea. The bottom of the flexible material is preferably convex relative to the shape of the eye. The outer diameter of the flexible material is conveniently fits over the ball of the eye. The surgical drape has an opening greater than or equal to the inner diameter and smaller than or equal to the outer diameter of the flexible material. The flexible material is removably fixed to the eye through a vacuum force caused by air expelled from, e.g. (i) a pocket of air in between the flexible material and the eye, (ii) a chamber with openings at the bottom of the flexible material, and / or (iii) a suction device.
Owner:MINO SOTELO DE KASPAR HERMINIA +2

Compounds for treating biofilm infection

ActiveUS20170143842A1Reduce and stopExtends antimicrobial efficacy of coatingCarbohydrate active ingredientsPharmaceutical non-active ingredientsBiofilmMedicine
In some aspects, pegylated aminoglycoside compounds are provided. In some embodiments, m-PEG-tobramycin compounds may be used to treat a biofilm infection or reduce or treat established biofilms. The present invention provides, in various aspects, compounds and methods for the treatment of infections, such as biofilm infections or chronic biofilm infections. The chronic biofilm infection may occur in wounds, implanted devices, immunocompromised patients, people with cystic fibrosis, eye infections, etc.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Uliflourxacin eye drop and preparation method thereof

The invention provides an uliflourxacin eye drop and a preparation method thereof. The uliflourxacin eye drop is directly prepared from uliflourxacin as a raw material, and per ml of uliflourxacin contains 1-5mg and auxiliary materials suitable for an eye drop preparation or injection water. The uliflourxacin eye drop provided by the invention is capable of effectively preventing and treating eye infection of sensitive bacteria, especially infection of Gram-negative bacteria including pseudomonas aeruginosa with increasing drug resistance, is high in bioavailability, long in standing time in eyes, remarkable in post-antibiotic effect, beneficial to reduction of a single dose of a drug, good in treatment effect, and low in cost; the preparation method is simple and convenient, is short in period, meets the large-scale production need, and has a practical significance for treating eye infectious diseases increasingly resisting drug.
Owner:GUANGZHOU PHARMACEUTICAL INDUSTRIAL RESEARCH INSTITUTE

Eyedrops for curing eye affection and uses thereof

The invention discloses an eye drop which mainly contains amikacin or amikacin salt and chitosan or the derivative of chitosan. The eye drop comes into being through the dissolving of a medicine compound into the injection water which is then added with leakage pressure adjusting agent, pH value adjusting agent, acid-bases buffer, chemical inhibitor and bacteriostatic agent, then the addition of the full dose of injection water after the dissolving, then the filtering and sterilization of the solution, with the finished product obtained finally after the canning and sealing. The invention, on one hand, reduces the dosage of amikacin through the coordinate antibacterial action of chitosan, the derivative of chitosan and the amikacin, thus reducing the toxic and side effect and particularly reducing the toxicity to ears and kidneys. On the other hand, the invention prolongs the time for which the medicine stays in the eyes through taking advantage of the solution with a certain viscosity obtained after the dissolving of chitosan and the derivative of chitosan into the water, thus improving the use efficiency of the medicine, reducing the medicine using times and prolonging the intervals for medicine using. The invention has a good result in curing the eye infection caused by sensitive bacteria, such as conjunctivitis, keratitis, sclerotitis, etc.
Owner:四川川投医药生物技术有限责任公司

Eye drops for treating eye infection containing levofloxacin, salt thereof or solvate of same, method for treating eye infection, levofloxacin, salt thereof or solvate of same, and utilization thereof

InactiveCN102770141AImprove short-term cure rateInhibition of resistant bacteriaAntibacterial agentsOrganic active ingredientsSide effectBacterial Conjunctivitis
Disclosed are a method and dosage of eye drops containing 1.5% (w / v) of levofloxacin, characterized in that, when the eye drops are dropped into the eyes thrice a day, bacterial conjunctivitis can be healed within a short period of time, compared with the conventional case where 0.5% (w / v) eye drops are used thrice a day, without increasing the incidence of side effects. Healing of an eye infection within a short period of time contributes to shortening of the exposure time of a pathogenic bacterium causing the eye infection to levofloxacin. As a result, it is expected that, when used in the aforesaid method and dosage, the levofloxacin-containing eye drops inhibit the appearance of a resistant strain which is caused by the prolonged usage of levofloxacin-containing eye drops in the conventional method or dosage. Moreover, it is confirmed that, when used in the aforesaid method and dosage, the levofloxacin-containing eye drops directly inhibit the appearance of resistance, which is caused by the short-term usage of levofloxacin-containing eye drops in the conventional method or dosage, in pathogenic bacteria causative of eye infections such as Staphylococcus aureus.
Owner:SANTEN PHARMA CO LTD +1

Onion capsules and preparation method thereof

The invention discloses onion capsules and a preparation method thereof. The onion capsules comprise following ingredients: 1 portion of dried onion powder which is a main raw material and is produced by drying and grinding fresh onion into powder; and 0.04 to 0.1 portion of dried butterflybush flower powder and 0.04 to 0.1 portion of dried liquorice powder, which are auxiliary materials. The onion capsules are produced by following steps: mixing the prepared dried onion powder, butterflybush flower powder and liquorice powder uniformly according to the portion of the formula; sterilizing the mixture; and dividing the mixture equally and encapsulating the mixture with capsule shells. The onion capsules of the invention can be accepted by people who dislike onion flavor, and is capable of decreasing blood glucose, lowering blood pressure, preventing and treating osteoporosis and cancers, preventing blood clots, enhancing sexual function, delaying senescence, and avoiding inflammation and eye infection which are caused by over taking.
Owner:袁明

High-safety ophthalmic eyewash equipment

The invention discloses high-safety ophthalmic eyewash equipment. The high-safety ophthalmic eyewash equipment comprises an eyewash equipment water collecting basin and an eyewash equipment drainage supporting column, one end of the eyewash equipment water collecting basin is fixedly connected with a face mirror frame, one end of the face mirror frame is fixedly connected with a face mirror, one end of the eyewash equipment drainage supporting column is connected with a transverse water inlet connecting pipe in a penetrating mode, one end of the transverse water inlet connecting pipe is fixedly connected with a first steering elbow, one end of the first steering elbow is fixedly connected with a water inlet pipe, one end of the water inlet pipe is connected with a rotary switch valve in apenetrating mode, one end of the rotary switch valve is provided with a rotary valve rod, one end of the rotary valve rod is fixedly connected with a rotary handle, a drainage through pipe is arrangedin the eyewash equipment drainage supporting column, and the other end of the transverse water inlet connecting pipe is fixedly connected with a second steering elbow. The eyewash equipment can be conveniently used, a spray head can be conveniently detached and replaced to prevent eye infection, safety and sanitation are achieved, internal protection is good, the service life is prolonged, and practicability is high.
Owner:WUHAN AIER EYE HOSPITAL CO LTD

Gatifloxacin, prednisolone, and bromfenac compositions and methods

ActiveUS20220062302A1Improve stabilitySimilar and improved stabilityOrganic active ingredientsSolution deliveryActive agentBromfenac
Provided here are new ophthalmologically suitable pharmaceutical compositions comprising an effective amount of gatifloxacin, prednisolone, and bromfenac. In aspects, the compositions are suspensions that include a suspension component comprising one or more suspension agents. In aspects, the suspension component includes an ionic suspension agent. In aspects, the composition also or alternatively comprises a non-ionic surfactant, non-ionic suspension agent, or both, or an agent that provides both functions. In aspects, such compositions further comprise an effective amount of a chelating agent / component. Further described are related compositions and methods of making and using such compositions, e.g., in the treatment of eye infections.
Owner:SOMERSET THERAPEUTICS LLC

Compounds for treating biofilm infection

In some aspects, pegylated aminoglycoside compounds are provided. In some embodiments, m-PEG-tobramycin compounds may be used to treat a biofilm infection or reduce or treat established biofilms. The present invention provides, in various aspects, compounds and methods for the treatment of infections, such as biofilm infections or chronic biofilm infections. The chronic biofilm infection may occur in wounds, implanted devices, immunocompromised patients, people with cystic fibrosis, eye infections, etc.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products